Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.

09/10/2026, 4:08 PM • The Motley Fool

2 Dividend Stocks Built to Hold Up When Markets Don't

The article recommends two Dividend Kings—Johnson & Johnson and AbbVie—as defensive dividend stocks that can provide steady income during market volatility. Both companies have demonstrated consistent dividend growth and strong business fundamentals in their pharmaceutical and healthcare portfolios.

09/09/2026, 10:10 AM • The Motley Fool

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.

09/08/2026, 2:30 PM • The Motley Fool

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

While Pfizer offers a higher dividend yield of 6.1%, AbbVie is positioned as the superior long-term dividend stock. AbbVie has demonstrated stronger revenue growth (138% over a decade vs. Pfizer's 18%), is a Dividend King with 53 consecutive years of dividend increases, and has successfully navigated the loss of Humira exclusivity through home-grown replacements Skyrizi and Rinvoq. In contrast, Pfizer faces significant patent cliff exposure between 2026-2028 with $17-18 billion in annual revenue at risk from generic competition.

09/08/2026, 12:45 PM • The Motley Fool

Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics

Cloverleaf Bio, a Yale spinout RNA therapeutics company, closed a $33 million oversubscribed seed round led by 4BIO Capital with strategic participation from AbbVie Ventures, Eli Lilly, and Boehringer Ingelheim Venture Fund. The funding will advance the company's engineered tRNA platform for cancer treatment, with lead programs targeting hepatocellular carcinoma and colorectal cancer. Preclinical data shows the platform demonstrates superior potency and selectivity for cancer cells over healthy tissue.

09/08/2026, 7:00 AM • GlobeNewswire

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider

The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.

09/07/2026, 6:52 AM • GlobeNewswire

Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - SNS Insider

The global atopic dermatitis drugs market is projected to grow from USD 15.92 billion in 2025 to USD 33.42 billion by 2035, driven by increased adoption of biologic therapies, JAK inhibitors, and novel treatments. North America leads with 36% market share, while Asia-Pacific shows the fastest growth. Biologics dominate with 42% market share, though high costs and JAK inhibitor safety warnings present challenges.

09/04/2026, 8:30 PM • GlobeNewswire

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.

09/04/2026, 2:30 PM • The Motley Fool

Want $500 a Month in Passive Income? Start With This Brilliant Dividend ETF.

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as an effective vehicle for generating sustainable passive income through dividends. With a 3.2% yield and a history of increasing annual dividends since 2011, investors would need approximately $187,500 invested to generate $500 monthly in dividend income. The fund focuses on high-quality dividend-paying stocks and has delivered 13.4% annual returns since inception.

09/04/2026, 5:22 AM • The Motley Fool

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ

Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.

09/02/2026, 12:12 PM • The Motley Fool

Vanguard Health Care ETF vs Simplify Health Care ETF

Vanguard Health Care ETF (VHT) offers broad healthcare exposure with a low 0.09% expense ratio and 1.5% dividend yield, while Simplify Health Care ETF (PINK) provides active management with higher 1-year returns (32.4% vs 29.3%) but charges 0.51% in fees. The author recommends Simplify despite Vanguard's better year-to-date performance, citing Simplify's superior longer-term returns and its pro bono model donating profits to breast cancer research.

09/01/2026, 3:12 PM • The Motley Fool

If You'd Invested $1,000 in SCHD 10 Years Ago, Here's How Much You'd Have Today

The Schwab U.S. Dividend Equity ETF (SCHD) has delivered approximately 13% annual returns over the past decade, turning a $1,000 investment into roughly $3,400 with reinvested dividends. The fund's stringent selection criteria focusing on balance sheet quality, yield, and dividend growth history have produced a durable, high-quality portfolio. The article emphasizes the importance of buy-and-hold investing through market downturns and consistent dividend reinvestment for long-term wealth creation.

08/31/2026, 9:30 AM • The Motley Fool

Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution Channel

The global palmoplantar pustulosis market is experiencing steady growth driven by increased awareness, diagnosis rates, and development of targeted biologic therapies. Key advances in IL-23 and IL-36 research, precision medicine, and AI-assisted diagnostics are accelerating treatment development. While topical therapies remain central for mild cases, systemic agents and biologics are supporting moderate-to-severe disease management. Growth is reinforced by clinical trials and regulatory approvals across North America, Europe, and Asia-Pacific, though high treatment costs and limited access in developing regions remain challenges.

08/31/2026, 5:03 AM • GlobeNewswire

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

The article compares AbbVie and Eli Lilly as pharmaceutical investment options for 2026. AbbVie focuses on immunology and neuroscience with revenue of $61.2B and faces patent expiration risks, while Eli Lilly is experiencing explosive 45% revenue growth driven by its GLP-1 drugs (Mounjaro and Zepbound) with projected 2026 revenue of $85.2B. Despite Eli Lilly's higher valuation, the article recommends it for long-term investors due to the sustained demand and lifecycle nature of its metabolic therapies.

08/29/2026, 3:15 PM • The Motley Fool

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

Revolution Medicines received rapid FDA approval for Rasonque, a novel pancreatic cancer treatment using a RAS inhibitor mechanism. The drug demonstrated strong Phase 3 trial results and analysts project peak annual sales of $11.5 billion. The stock has surged 178% year-to-date, with potential for further expansion into other cancer indications affecting 30% of solid tumors.

08/28/2026, 7:07 AM • The Motley Fool